A Phase 3 interventional study of 177Lu-PSMA-617 and 68Ga-PSMA-11 in Prostatic Neoplasms, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 164 sites in 19 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, B…PubMed 42561994 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.
Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one has the largest enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, reaches primary completion later than 2 of the 30 other live ones, and was the 12th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Mayo Clinic · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
Jean-Mathieu Beauregard · Sites in Canada
Ages 18+ · Men only
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 4 · Phase 4 2
First in 2016; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,144 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 49 across the 41 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
82 studies in Prostatic Neoplasms by Novartis: 13 open now, 25 under way, 4 of them phase 3. Of 54 finished, 11 (20%) have results posted.
Among the 82 studies in Prostatic Neoplasms by Novartis, this one has the largest enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 1 of the 24 other live ones, and was the 49th registered.
Novartis’s Prostatic Neoplasms studies by the year they started, since 1999.
10 of the studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05849298Novartis PharmaceuticalsA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | 2026-12-23 |
| NCT06145633Fred Hutchinson Cancer CenterVorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | 2026-12-30 |
| NCT06574880Angela Y. Jia, MD PhDSTereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer | 2027-01-01 |
| NCT06288113Jonsson Comprehensive Cancer CenterRe-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | 2027-01-27 |
| NCT06972628Ebrahim S DelpassandTreatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | 2027-04-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, from their registry updates:
Among Novartis’s 82 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.
In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC were to be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.
The primary objective of the study was to determine whether the combination of 177Lu-PSMA-617 + SoC improved radiographic progression free survival (rPFS) over that obtained by administration of SoC alone in mHSPC patients.
The randomization was stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no).
Planned study duration: approximately 50 months. screening period: after signing ICF, patients were assessed for eligibility and were scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant was randomized via the interactive response technology (IRT) system.
Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at Radiographic progressive disease (rPD) following Blind Independent Review Committee (BIRC) confirmed rPD in both arms.
Prior treatment:
Randomization period:
The participant was randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.
Treatment period:
Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients received SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients began 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product was received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles.
Patients randomized to the control arm began receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol.
The primary endpoint of rPFS was assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician.
Participants from both arms also underwent PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD.
An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment.
Cross-over period:
After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =\< 7 days and enter the Post-treatment Follow-up.
Post-Treatment Follow-Up (Safety, Efficacy):
After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months.
Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first.
Survival Follow-Up:
After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants eligible for inclusion in this study must meet all of the following criteria:
Patients must have at least one documented metastatic bone and/or soft tissue/visceral lesion documented in the following manners within 28 days prior randomization:
Patients must have adequate organ function:
Treatment naïve OR minimally treated with:
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible for inclusion in this study.
Active cardiac disease defined as any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); Androgen receptor-directed therapy (ARDT) + Androgen deprivation therapy (ADT) is considered as SOC and treatment will be administered per the physician's order
Drug: 177Lu-PSMA-617 · Drug: 68Ga-PSMA-11 · Drug: ARDT · Drug: ADT
For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
Drug: 68Ga-PSMA-11 · Drug: ARDT · Drug: ADT
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Also known as: AAA617
Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Also known as: AAA517
Administered orally on a continuous basis as per package insert and guideline
ADT are administered as per physician order
Radiographic Progression Free Survival (rPFS)
rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
Overall Survival (OS) (Key Secondary Endpoint)
OS is defined as time to death for any cause
Time frame: From date of randomization until date of death from any cause, assessed up to approx. 43 months
Prostate-specific Antigen 90 (PSA90) Response
PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months.
Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
Time to Development of mCRPC
Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.
Time frame: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
Progression Free Survival (PFS)
PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first
Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Second Progression Free Survival (PFS2)
PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.
Time frame: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Change in Nadir Level of PSA Lower Than 0.2 ng/ml
Percentage of participants with PSA \< 0.2 ng/mL at months 12, 24 and 48 months/
Time frame: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
Time to Radiographic Soft Tissue Progression (TTSTP)
TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR).
Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Time to First Symptomatic Skeletal Event (SSE)
Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.
Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
Overall Response Rate (ORR)
ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.
Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Disease Control Rate (DCR)
DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.
Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Duration of Response (DOR)
DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Time to Response (TTR)
TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).
Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
Time frame: From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)
EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual.
Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Brief Pain Inventory-short Form (PBI-SF)
The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.
Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
1144 participants were enrolled from 19 countries, although 20 countries participated in the study.
| Milestone | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) |
|---|---|---|
| Started | 572 | 572 |
| Treated | 567 | 562 |
| Not treated | 5 | 10 |
| Discontinued from treatment | 187 | 229 |
| Ongoing treatment | 380 | 333 |
| Crossover participants (from soc to 177lu-psma-617) | 0 | 91 |
| Completed | 380 | 333 |
| Not completed | 192 | 239 |
| Withdrew: Physician decision | 49 | 42 |
| Withdrew: Withdrawal by subject | 28 | 31 |
| Withdrew: Adverse event | 27 | 20 |
| Withdrew: Death | 16 | 15 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Progressive disease | 64 | 118 |
| Withdrew: Not treated | 5 | 10 |
rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan.
| months | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) |
|---|---|---|
| Radiographic Progression Free Survival (rPFS) | NA (NA to NA) | NA (29.73 to NA) |
OS is defined as time to death for any cause
| months | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) |
|---|---|---|
| Overall Survival (OS) (Key Secondary Endpoint) | NA (NA to NA) | NA (NA to NA) |
PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months.
Results for this outcome have not been posted.
Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.
Results for this outcome have not been posted.
PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first
Results for this outcome have not been posted.
PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.
Results for this outcome have not been posted.
Percentage of participants with PSA \< 0.2 ng/mL at months 12, 24 and 48 months/
Results for this outcome have not been posted.
TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR).
Results for this outcome have not been posted.
Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.
Results for this outcome have not been posted.
ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.
Results for this outcome have not been posted.
DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.
Results for this outcome have not been posted.
DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause.
Results for this outcome have not been posted.
TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).
Results for this outcome have not been posted.
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
Results for this outcome have not been posted.
EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual.
Results for this outcome have not been posted.
The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.
Results for this outcome have not been posted.
Collected over On-treatment periods (assessed up to ~43 months): Lu+SoC, from 1st Lu dose to the later of 30 days after EOT/ARDT discontinuation or 41 days after last Lu dose SoC alone, from 1st post-randomization ARDT dose to the later of 30 days after last ARDT dose or EOT, ending before crossover Crossover Lu±SoC, from 1st crossover Lu dose to the later of 30 days after EOT or 41 days after last Lu dose Post-treatment periods: from end of treatment (or crossover treatment as applicable) to ~43 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-treatment Period 177Lu-PSMA-617 + SoC | 20/572 (3.5%) | 180/564 (31.9%) | 538/564 (95.4%) |
| On-treatment Period SoC Alone | 22/572 (3.8%) | 162/565 (28.7%) | 517/565 (91.5%) |
| On-treatment Period Crossover 177Lu-PSMA-617 +/- SoC | 9/91 (9.9%) | 27/91 (29.7%) | 74/91 (81.3%) |
| Post-treatment Period 177Lu-PSMA-617 + SoC | 65/572 (11.4%) | 14/564 (2.5%) | 20/564 (3.5%) |
| Post-treatment Period SoC Alone | 37/572 (6.5%) | 0/565 (0%) | 0/565 (0%) |
| Post-treatment Period Crossover 177Lu-PSMA-617 +/- SoC | 31/91 (34.1%) | 3/91 (3.3%) | 3/91 (3.3%) |
| Event | On-treatment Period 177Lu-PSMA-617 + SoC | On-treatment Period SoC Alone | On-treatment Period Crossover 177Lu-PSMA-617 +/- SoC | Post-treatment Period 177Lu-PSMA-617 + SoC | Post-treatment Period SoC Alone | Post-treatment Period Crossover 177Lu-PSMA-617 +/- SoC |
|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 2/564 | 7/565 | 3/91 | 0/564 | 0/565 | 0/91 |
| HaematuriaRenal and urinary disorders | 4/564 | 7/565 | 3/91 | 0/564 | 0/565 | 0/91 |
| AnaemiaBlood and lymphatic system disorders | 6/564 | 5/565 | 2/91 | 0/564 | 0/565 | 1/91 |
| Cardiac failureCardiac disorders | 0/564 | 1/565 | 2/91 | 0/564 | 0/565 | 0/91 |
| VomitingGastrointestinal disorders | 3/564 | 0/565 | 2/91 | 0/564 | 0/565 | 0/91 |
| General physical health deteriorationGeneral disorders | 6/564 | 4/565 | 1/91 | 1/564 | 0/565 | 2/91 |
| Urinary tract infectionInfections and infestations | 4/564 | 7/565 | 2/91 | 1/564 | 0/565 | 0/91 |
| Acute kidney injuryRenal and urinary disorders | 7/564 | 5/565 | 1/91 | 1/564 | 0/565 | 0/91 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 5/564 | 7/565 | 1/91 | 1/564 | 0/565 | 0/91 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/564 | 0/565 | 1/91 | 1/564 | 0/565 | 0/91 |
| Event | On-treatment Period 177Lu-PSMA-617 + SoC | On-treatment Period SoC Alone | On-treatment Period Crossover 177Lu-PSMA-617 +/- SoC | Post-treatment Period 177Lu-PSMA-617 + SoC | Post-treatment Period SoC Alone | Post-treatment Period Crossover 177Lu-PSMA-617 +/- SoC |
|---|---|---|---|---|---|---|
| Dry mouthGastrointestinal disorders | 258/564 | 21/565 | 35/91 | 1/564 | 0/565 | 1/91 |
| Hot flushVascular disorders | 164/564 | 204/565 | 3/91 | 1/564 | 0/565 | 0/91 |
| FatigueGeneral disorders | 196/564 | 157/565 | 16/91 | 0/564 | 0/565 | 0/91 |
| NauseaGastrointestinal disorders | 193/564 | 53/565 | 24/91 | 0/564 | 0/565 | 0/91 |
| AnaemiaBlood and lymphatic system disorders | 149/564 | 75/565 | 18/91 | 6/564 | 0/565 | 0/91 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 111/564 | 129/565 | 9/91 | 1/564 | 0/565 | 0/91 |
| Back painMusculoskeletal and connective tissue disorders | 100/564 | 108/565 | 7/91 | 3/564 | 0/565 | 0/91 |
| ConstipationGastrointestinal disorders | 101/564 | 90/565 | 11/91 | 1/564 | 0/565 | 0/91 |
| HypertensionVascular disorders | 74/564 | 95/565 | 4/91 | 0/564 | 0/565 | 1/91 |
| AstheniaGeneral disorders | 92/564 | 73/565 | 12/91 | 1/564 | 0/565 | 0/91 |
The FAS comprised all patients to whom study treatment was assigned by randomization.
| Age, Continuous(years) | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Mean | 67.7 ± 8.54 | 67.6 ± 8.34 | 67.6 ± 8.44 |
| Age, Customized(Participants) | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Adults (18-64 years) | 185 | 191 | 376 |
| From 65-84 years | 376 | 372 | 748 |
| 85 years and over | 11 | 9 | 20 |
| Sex/Gender, Customized(Participants) | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Male | 572 | 572 | 1144 |
| Race/Ethnicity, Customized(Participants) | 177Lu-PSMA-617 + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 101 | 118 | 219 |
| Black or African American | 26 | 29 | 55 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 356 | 345 | 701 |
| Unknown | 88 | 77 | 165 |
Showing the first 100 of 164 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to participant-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2021 to primary completion in Jan 2025, 43 months.
Results were first posted in Nov 2026, 1 year 9 months after primary completion. A results delay was requested in Jan 2026.
Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 43 months is above that.
Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Aug 2028, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, B…PubMed 42561994 ↗
Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, B…PubMed 42561994 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan